Boserolimab
- Generic Name
- Boserolimab
- Drug Type
- Biotech
- CAS Number
- 2444297-08-7
- Unique Ingredient Identifier
- 576SCZ7V2P
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- Conditions
- Early Triple Negative Breast Cancer
- Interventions
- Drug: Doxorubicin (hydrochloride)Drug: Olaparib (if approved/available locally)
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06829199
- Locations
- 🇺🇸
Optum Care Cancer Center ( Site 0004), Las Vegas, Nevada, United States
🇨🇳National Cheng Kung University Hospital ( Site 0901), Tainan, Taiwan
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT04924101
- Locations
- 🇺🇸
UPMC Hillman Cancer Center ( Site 0127), Pittsburgh, Pennsylvania, United States
🇺🇸MFSMC-HJWCI-Oncology Research ( Site 0128), Baltimore, Maryland, United States
🇺🇸Cleveland Clinic-Taussig Cancer Center ( Site 0116), Cleveland, Ohio, United States
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 135
- Registration Number
- NCT04165096
- Locations
- 🇺🇸
Cleveland Clinic Main ( Site 0006), Cleveland, Ohio, United States
🇺🇸Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States
🇺🇸City of Hope ( Site 0014), Duarte, California, United States
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Biological: HER3-DXdBiological: Ifinatamab Deruxtecan (I-DXd)
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT04165070
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States
🇺🇸City of Hope ( Site 0014), Duarte, California, United States
🇺🇸UCSF Medical Center at Mission Bay ( Site 0007), San Francisco, California, United States
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
- Conditions
- Solid TumorPharmacokineticsCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 184
- Registration Number
- NCT03396445
- Locations
- 🇺🇸
Florida Cancer Specialists ( Site 0002), Sarasota, Florida, United States
🇮🇱Soroka Medical Center-Oncology ( Site 0012), Be'er Sheva, Israel
🇺🇸The West Clinic, P.C. ( Site 0021), Germantown, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.